Filtered By:
Condition: Heart Disease
Cancer: Bladder Cancer

This page shows you your search results in order of date.

Order by Relevance | Date

Total 21 results found since Jan 2013.

Non-occupational physical activity and risk of cardiovascular disease, cancer and mortality outcomes: a dose-response meta-analysis of large prospective studies
Conclusions Inverse non-linear dose–response associations suggest substantial protection against a range of chronic disease outcomes from small increases in non-occupational physical activity in inactive adults. PROSPERO registration number CRD42018095481.
Source: British Journal of Sports Medicine - July 20, 2023 Category: Sports Medicine Authors: Garcia, L., Pearce, M., Abbas, A., Mok, A., Strain, T., Ali, S., Crippa, A., Dempsey, P. C., Golubic, R., Kelly, P., Laird, Y., McNamara, E., Moore, S., de Sa, T. H., Smith, A. D., Wijndaele, K., Woodcock, J., Brage, S. Tags: Open access, BJSM Reviews with MCQs, BJSM Systematic review Source Type: research

Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers
Raritan, NJ, Feb. 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that 17 presentations will be featured at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place in San Francisco and virtually from February 17-19. Building on its long-term leadership in prostate cancer, Janssen is committed to advancing innovative treatments and transforming patient experiences, while focusing on research that may drive better outcomes for people across the genitourinary cancer spectrum. Data to be presented include Phase 3 results for the selective ...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Physical inactivity and non-communicable disease burden in low-income, middle-income and high-income countries
Conclusion The global burden associated with physical inactivity is substantial. The relative burden is greatest in high-income countries; however, the greatest number of people (absolute burden) affected by physical inactivity are living in middle-income countries given the size of their populations.
Source: British Journal of Sports Medicine - January 3, 2022 Category: Sports Medicine Authors: Katzmarzyk, P. T., Friedenreich, C., Shiroma, E. J., Lee, I.-M. Tags: Editor's choice, Press releases, BJSM Original research Source Type: research

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease,” sai...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Physical inactivity and non-communicable disease burden in low-income, middle-income and high-income countries
CONCLUSION: The global burden associated with physical inactivity is substantial. The relative burden is greatest in high-income countries; however, the greatest number of people (absolute burden) affected by physical inactivity are living in middle-income countries given the size of their populations.PMID:33782046 | DOI:10.1136/bjsports-2020-103640
Source: British Journal of Sports Medicine - March 30, 2021 Category: Sports Medicine Authors: Peter T Katzmarzyk Christine Friedenreich Eric J Shiroma I-Min Lee Source Type: research

Arsenic exposure: A public health problem leading to several cancers
Publication date: Available online 23 November 2019Source: Regulatory Toxicology and PharmacologyAuthor(s): I. Palma-Lara, M. Martínez-Castillo, J.C. Quintana-Pérez, M.G. Arellano-Mendoza, F. Tamay-Cach, O.L. Valenzuela-Limón, E.A. García-Montalvo, A. Hernández-ZavalaAbstractArsenic, a metalloid and naturally occurring element, is one of the most abundant elements in the earth's crust. Water is contaminated by arsenic through natural sources (underground water, minerals and geothermal processes) and anthropogenic sources such as mining, industrial processes, and the production and use of pesticides. Humans are exposed...
Source: Regulatory Toxicology and Pharmacology - November 23, 2019 Category: Toxicology Source Type: research

Arsenic exposure: A public health problem leading to several cancers.
Abstract Arsenic, a metalloid and naturally occurring element, is one of the most abundant elements in the earth's crust. Water is contaminated by arsenic through natural sources (underground water, minerals and geothermal processes) and anthropogenic sources such as mining, industrial processes, and the production and use of pesticides. Humans are exposed to arsenic mainly by drinking contaminated water, and secondarily through inhalation and skin contact. Arsenic exposure is associated with the development of vascular disease, including stroke, ischemic heart disease and peripheral vascular disease. Also, arseni...
Source: Regulatory Toxicology and Pharmacology : RTP - November 21, 2019 Category: Toxicology Authors: Palma-Lara I, Martínez-Castillo M, Quintana-Pérez JC, Arellano-Mendoza MG, Tamay-Cach F, Valenzuela-Limón OL, García-Montalvo EA, Hernández-Zavala A Tags: Regul Toxicol Pharmacol Source Type: research

Periodontal Disease Is Associated With Increased Risk of Hypertension: A Cross-Sectional Study
Conclusion: Periodontal disease is significantly and positively correlated with increased risk of hypertension in Chinese population, and exact mechanisms of this association should be explored in future. Introduction Periodontal disease is a complex polymicrobial inflammation, including gingivitis and periodontitis. According to the 2015 Global Burden of Disease (GBD) study, the prevalence of severe chronic periodontitis in 2015 has reached 616 million (Kassebaum et al., 2017). In China, the periodontal disease standardized DALYs rate has risen from 24.7 in 1990 to 25.7 in 2013 according to the data from 2013 GBD ...
Source: Frontiers in Physiology - April 24, 2019 Category: Physiology Source Type: research

BMI and Mortality in UK Biobank: Revised Estimates Using Mendelian Randomization.
CONCLUSIONS: Results support a causal role of higher BMI in increasing the risk of all-cause mortality and mortality from several specific causes. PMID: 30358150 [PubMed - in process]
Source: Obesity - October 27, 2018 Category: Eating Disorders & Weight Management Authors: Wade KH, Carslake D, Sattar N, Davey Smith G, Timpson NJ Tags: Obesity (Silver Spring) Source Type: research